阿托伐他汀对大脑中动脉支架置入术不良事件的影响

阿托伐他汀对大脑中动脉支架置入术不良事件的影响
柯伟;焦力群;李文澜;邓小容
【期刊名称】《中国脑血管病杂志》
【年(卷),期】2011(8)4
【摘要】Objectives To investigate the effect of atorvastatin on the adverse events after middle cerebral artery stenting. Methods Twenty-four patients who successfully completed middle cerebral artery stenting ( restenosis rate ≥70％ ) were randomly assigned to 2 groups: treatment group ( taking atorvastatin 40 mg + plavix 75mg + aspirin enteric-coated tablet 300 mg, once a day) and control group ( taking plavix 75mg + aspirin enteric-coated tablet 100 mg, once a day) (n = 12 in each group). The patients were followed up at 1, 3, 6, and 12 months after procedure. New adverse events (transient ischemic attack, cerebral inlarction, restenosis, and reintervention) were recorded. Results Compared with the control group, the blood lipid level and C-reactive protein level were decreased significantly at all time points in the treatment group ( P ＜ 0. 05 or P ＜ 0.01 ), except the LDL-C level at 1 month. The total incidence of adverse events in the treatment group was lower than that in the control group. There was statistically significant difference (P =0.00017); however, the C-reactive protein level was higher than that before procedure, and it was lower than that before procedure until 12 months. The blood lipid level after procedure was significantly lower than that before procedure in
the treatment group. Conclusion Atorvastatin treatment after middle cerebral artery stenting may effectively prevent the occurrence of adverse events after stenting.%目的在大脑中动脉支架置入的患者中应用阿托伐他汀进行干预,探讨阿托伐他汀对不良事件及血脂和C-反应蛋白的影响.方法将24例大脑中动脉狭窄(狭窄率≥70%)成功完成大脑中动脉支架置入术的患者随机分为两组,每组12例.治疗组:口服用阿托伐他汀40 mg+氯吡格雷75 mg+拜阿司匹林
100nag,1 次/d;对照组:硫酸氢氯吡格雷75 mg+拜阿司匹林100 mg,1次/d.支架置入术后1个月、3个月、6个月、12个月进行随访,记录两组的各阶段新发的不良事件(短暂性脑缺血发作、脑梗死、再狭窄、再次介入治疗).并检测术前及术后不同时间点血脂及C-反应蛋白的水平.结果与对照组比较,除1个月时的低密度脂蛋白胆固醇水平外,其余各时间点治疗组血脂及C-反应蛋白水平均低于对照组
(P<0.05或P<0.01);总不良事件的发生率,治疗组低于对照组,差异有统计学意义(P=O.000 17);而C-反应蛋白术后较术前升高,至12个月时低于术前;治疗组术后血脂水平较术前明显降低.结论大脑中动脉支架置入术后使用阿托伐他汀治疗可有效地预防支架置入术后不良事件的发生;阿托伐他汀可使患者术后的血脂和C-反应蛋白降低.
【总页数】4页(P185-188)
【作者】柯伟;焦力群;李文澜;邓小容
【作者单位】430033,武汉,湖北省中山医院神经内科;首都医科大学宣武医院神经外科;武汉大学人民医院麻醉科;430033,武汉,湖北省中山医院神经内科
【正文语种】中文
【相关文献】
1.症状性大脑中动脉狭窄患者支架置入术对脑血管反应性的影响 [J], 高宇海;石进;张英谦;陈大伟;张卫清;时惠平
2.症状性大脑中动脉狭窄患者支架置入术后再狭窄影响因素的分析 [J], 贺雄军;缪中荣;凌锋;华扬;李慎茂;朱凤水;吉训明;焦力群
3.应用ASPECTS评价影响大脑中动脉狭窄患者支架置入术前后CT灌注的相关因素 [J], 曲辉;张长青;董可辉
4.大脑中动脉支架置入后阿托伐他汀对缺血性不良事件的影响:24例12个月随访[J], 李文澜;柯伟;邓小容
5.不同阿托伐他汀方案对大脑中动脉支架植入治疗急性脑梗死病人血流动力学、脑血管事件发生率的影响 [J], 霍俊婷;王墨力;宋立刚
因版权原因，仅展示原文概要，查看原文内容请购买。